Bao Pharma-B Repurchases HK$3.99 Million in Shares, Treasury Stock Rises to 2.40 Million

Bulletin Express09-03 20:22

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed a share buyback of 240,900 H-shares on 3 September 2026. The repurchase, executed on the Hong Kong Stock Exchange under the existing mandate granted on 26 May 2026, was completed at prices ranging from HK$16.15 to HK$17.12 per share, with a volume-weighted average cost of HK$16.5688. The total consideration amounted to HK$3.99 million.

Following the transaction, issued shares outstanding (excluding treasury shares) decreased to 151.93 million, down 0.16% from the 152.17 million recorded on 2 September 2026. Treasury shares increased by the same amount to 2.40 million, while the company’s total issued share count remained unchanged at 154.33 million.

Cumulatively, Bao Pharma-B has repurchased 2.40 million shares—equivalent to 1.55% of the issued share base at the time the mandate was approved—against its authorisation to buy back up to 15.43 million shares. All repurchased shares are currently held in treasury; no cancellations or on-market disposals have been executed. Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share sales until 3 October 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158121017?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158121017","market":"hk","top_or_hot":-1,"title":"Bao Pharma-B Repurchases HK$3.99 Million in Shares, Treasury Stock Rises to 2.40 Million","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed a share buyback of 240,900 H-shares on 3 September 2026. The repurchase, executed on the Hong Kong Stock Exchange under the existing mandate granted on 26 May 2026, was completed at prices ranging from HK$16.15 to HK$17.12 per share, with a volume-weighted average cost of HK$16.5688. The total consideration amounted to HK$3.99 million.</p>\n<p>Following the transaction, issued shares outstanding (excluding treasury shares) decreased to 151.93 million, down 0.16% from the 152.17 million recorded on 2 September 2026. Treasury shares increased by the same amount to 2.40 million, while the company’s total issued share count remained unchanged at 154.33 million.</p>\n<p>Cumulatively, Bao Pharma-B has repurchased 2.40 million shares—equivalent to 1.55% of the issued share base at the time the mandate was approved—against its authorisation to buy back up to 15.43 million shares. All repurchased shares are currently held in treasury; no cancellations or on-market disposals have been executed. Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share sales until 3 October 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma-B Repurchases HK$3.99 Million in Shares, Treasury Stock Rises to 2.40 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma-B Repurchases HK$3.99 Million in Shares, Treasury Stock Rises to 2.40 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-03 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed a share buyback of 240,900 H-shares on 3 September 2026. The repurchase, executed on the Hong Kong Stock Exchange under the existing mandate granted on 26 May 2026, was completed at prices ranging from HK$16.15 to HK$17.12 per share, with a volume-weighted average cost of HK$16.5688. The total consideration amounted to HK$3.99 million.</p>\n<p>Following the transaction, issued shares outstanding (excluding treasury shares) decreased to 151.93 million, down 0.16% from the 152.17 million recorded on 2 September 2026. Treasury shares increased by the same amount to 2.40 million, while the company’s total issued share count remained unchanged at 154.33 million.</p>\n<p>Cumulatively, Bao Pharma-B has repurchased 2.40 million shares—equivalent to 1.55% of the issued share base at the time the mandate was approved—against its authorisation to buy back up to 15.43 million shares. All repurchased shares are currently held in treasury; no cancellations or on-market disposals have been executed. Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share sales until 3 October 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1158121017","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158121017","pubTimestamp":1788438178,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed a share buyback of 240,900 H-shares on 3 September 2026. The repurchase, executed on the Hong Kong Stock Exchange under the existing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝医药B回购399万港元股份，库存股增至240万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed a share buyback of 240,900 H-shares on 3 September 2026. The repurchase, executed on the Hong Kong Stock Exchange under the existing mandate granted on 26 May 2026, was completed at prices ranging from HK$16.15 to HK$17.12 per share, with a volume-weighted average cost of HK$16.5688. The total consideration amounted to HK$3.99 million.\nFollowing the transaction, issued shares outstanding (excluding treasury shares) decreased to 151.93 million, down 0.16% from the 152.17 million recorded on 2 September 2026. Treasury shares increased by the same amount to 2.40 million, while the company’s total issued share count remained unchanged at 154.33 million.\nCumulatively, Bao Pharma-B has repurchased 2.40 million shares—equivalent to 1.55% of the issued share base at the time the mandate was approved—against its authorisation to buy back up to 15.43 million shares. All repurchased shares are currently held in treasury; no cancellations or on-market disposals have been executed. Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share sales until 3 October 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158121017","isCrawlerRequest":true}